


Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E




Figure 2F




Figure 2G




Figure 3A



Fresh Tregs n=3
Expanded Tregs n=3
% positive cells in CD8+CD45RClow Tregs
0
20
40
60
80
100
IL-34
TGFb1
FoxP3
IFNg
Tbet
GITR
PD-1
CD127
CD28
CD27
CD45RA
HLA-DR
CD154
CD103

Figure 3B




Figure 4A





Figure 4B






Figure 5A

Figure 5B



CD4+ T cells
CD8+ T cells
CD45RC
undifferenciated
Cultured with IL34-differenciated macrophages
Cultured with MCSF-differenciated macrophages
11,2%
0,338%
79,4%
9,06%
16,6%
0,377%
80,1%
2,89%
0,907%
0,051%
57,4%
41,6%
5,32%
0,181%
77,0%
17,5%
2,09%
0,067%
76,3%
21,5%
11,2%
0,064%
82,3%
6,44%
Foxp3

Figure 6




Figure 7A




Figure 7B




Figure 7C



%positive cells among IL34 differenciated macrophages
100
80
60
40
20
0
*
CD14+CD16- (n=2 à 4)
CD14-CD16+ (n=2 à 4)
CD14+CD16- (n=2 à 4)
CD86
CD80
CD40
CD14
CD163
CD209a
CD36
CD1a
M1 associated markers
M2 associated markers
DC associated markers

Figure 7D



Day 3
% survival
200
150
100
50
0
CD14+ CD16-
CD14- CD16+
CD14+ CD16+
Day 4
% survival
400
300
200
100
0
CD14+ CD16-
CD14- CD16+
CD14+ CD16+

Figure 8A



CD14+CD16-
CD14-CD16+
Day 3
Day 4
CD86
CD80
CD40
CD36
CD163
CD14
CD1a

Figure 8B (1/2)



CD14+CD16+
Day 3
Day 4
M1-associated markers
M2-associated markers
CD86
CD80
CD40
CD36
CD163
CD14
CD1a

Figure 8B (2/2)